Records containing: Urothelial Carcinoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-04-13Optimal Screening Strategy for Bladder Cancer in at Risk Patients
-
CLINICAL_TRIALS study record update · 2025-04-11Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER: Multicenter Retrospective Study (Real World Evidence - RWE)
-
CLINICAL_TRIALS study record update · 2025-04-09An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab as First-line Treatment in Cisplatin-ineligible Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma
-
CLINICAL_TRIALS study record update · 2025-04-08Performance Evaluation of a Urine-based Methylation Assay for Urothelial Carcinoma in Patients With Hematuria: A Prospective, Multi-center Cohort Study
-
CLINICAL_TRIALS study record update · 2025-04-02ARON-2 Study-Multicentric International Retrospective Study
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-04-01Retrospective, Multicenter, Observational Study to Evaluate Current Treatment Patterns and Outcomes in Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With First-line Avelumab Maintenance
-
CLINICAL_TRIALS study record update · 2025-03-26Adjuvant Sacituzumab Govitecan Plus Nivolumab in Patients with Muscle-Invasive Urothelial Carcinoma At High-Risk for Recurrence
-
CLINICAL_TRIALS study record update · 2025-03-21Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff
-
CLINICAL_TRIALS study record update · 2025-03-21A Randomized Phase II Trial to Evaluate 9MW2821 in Combination With Toripalimab Compared With 9MW2821 Monotherapy for the 1st Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
-
CLINICAL_TRIALS study record update · 2025-03-18Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
-
CLINICAL_TRIALS study record update · 2025-03-14Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas
-
CLINICAL_TRIALS study record update · 2025-03-12Predicting Immunotherapy Efficacy from Analysis of Pre-treatment Tumor Biopsies
-
CLINICAL_TRIALS study record update · 2025-03-10An Open-Label, Randomized, Phase 2, Umbrella Study to Investigate the Biological Rational of Various Neoadjuvant Therapies for Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy
-
CLINICAL_TRIALS study record update · 2025-03-06ICRA (Improve Checkpoint-blockade Response in Advanced Urothelial Cancer), an Adaptive Clinical Study to Determine Efficacy of Combining Weekly Paclitaxel With Tremelimumab +/- Durvalumab (MEDI4736)
-
CLINICAL_TRIALS study record update · 2025-03-05A Phase 1b Trial in Stage II-III Urothelial Cancer to Explore Pre-operative Immunotherapy
-
CLINICAL_TRIALS study record update · 2025-03-05Phase 1B Study to Assess Safety and Efficacy of Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NABUCCO)
-
CLINICAL_TRIALS study record update · 2025-02-28uTRACT Jelmyto Registry: A Multicenter, Prospective and Retrospective Registry to Evaluate Real World Experience and Outcomes of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
-
CLINICAL_TRIALS study record update · 2025-02-28ClinicalTrials.gov study NCT05494411
-
CLINICAL_TRIALS study record update · 2025-02-25A Phase II Study of Intermittent Checkpoint Inhibitor Therapy in Patients With Advanced Urothelial Carcinoma
-
CLINICAL_TRIALS study record update · 2025-02-21QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Therapy
-
CLINICAL_TRIALS study record update · 2025-02-17A Phase 1/2 Study Using Nivolumab and ABI-009 for Advanced Sarcoma, Advanced Carcinoma Treated With PD1 Inhibitors, and Tumors With Genetic Mutations Sensitive to mTOR Inhibitors
-
CLINICAL_TRIALS study record update · 2025-02-13A Multicenter, Single-blind, Observational Clinical Trial of URISAFE
-
CLINICAL_TRIALS study record update · 2025-02-12A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 as a Single Agent and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-02-03A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers
-
CLINICAL_TRIALS study record update · 2025-01-27A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination With Nivolumab, an Anti-PD-1 Antibody, for Subjects With HER2-expressing Advanced Breast and Urothelial Cancer